Outcomes in patients with unresected glioblastoma including assessment of treatment with bevacizumab as a component of initial therapy
| Autor: | James T. Symanowski, Renee P Kelly, Ashley Sumrall, Mark D Smith, Stuart H. Burri, Peggy O Boltes, Daniel Haggstrom, Roshan S. Prabhu, Robert Fraser, Anthony L. Asher, William E Ballinger |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Temozolomide Bevacizumab business.industry medicine.medical_treatment Newly diagnosed medicine.disease nervous system diseases Surgery Radiation therapy Unresected Internal medicine medicine In patient business Initial therapy medicine.drug Glioblastoma |
| Zdroj: | Journal of Clinical Oncology. 32:2069-2069 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2014.32.15_suppl.2069 |
| Popis: | 2069 Background: Radiation therapy (RT) and concurrent temozolomide (CRT) is the accepted standard for newly diagnosed glioblastoma (GBM). Despite promising results in recurrent settings, addition ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|